Bayer (FRA:BAYN) has been assigned a €110.00 ($127.91) price objective by analysts at UBS Group in a research note issued to investors on Tuesday, www.boersen-zeitung.de reports. The firm currently has a “buy” rating on the healthcare company’s stock. UBS Group’s price objective suggests a potential upside of 61.96% from the company’s current price.
Several other equities analysts have also recently issued reports on BAYN. Kepler Capital Markets set a €84.00 ($97.67) price objective on Bayer and gave the stock a “buy” rating in a report on Tuesday. JPMorgan Chase & Co. set a €70.00 ($81.40) price objective on Bayer and gave the stock a “neutral” rating in a report on Tuesday. Sanford C. Bernstein set a €86.00 ($100.00) price objective on Bayer and gave the stock a “buy” rating in a report on Friday. Deutsche Bank set a €115.00 ($133.72) price objective on Bayer and gave the stock a “buy” rating in a report on Monday. Finally, Credit Suisse Group set a €77.00 ($89.53) price objective on Bayer and gave the stock a “buy” rating in a report on Tuesday, November 27th. Seven analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of €88.37 ($102.76).
Shares of BAYN stock opened at €67.92 ($78.98) on Tuesday. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Recommended Story: How to find the components of the quick ratio
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.